Nevertheless, a phase IIb clinical trial in patients with recurrent GBM is ongoing to evaluate the anti-tumor activity of pembrolizumab (MK-3475, a PD-1 monoclonal antibody) alone or in combination of PI3K/Akt inhibitors including GDC-0941, NVP-BEZ235 and GDC-0068 (NCT02430363). This evidence concerns the gene PIK3CB and glioblastoma.